PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, has announced positive results from its human clinical trials investigating the efficacy of PRF-110 in wound healing and scar prevention. PRF-110 is the company’s lead asset designed to provide extended, non-opiate, post-surgical pain relief.
The recent human clinical trials included patients undergoing both hard tissue (bunionectomy) and soft tissue (hernia) surgeries. Results from these trials indicated no abnormalities in wound healing or scar formation among patients treated with PRF-110. Wound healing in all patients was complete and consistent with outcomes expected from surgeries without PRF-110.
PRF-110’s formulation, which includes approximately 55% lecithin, has shown to form liposome-like structures upon contact with body fluids. Existing literature suggests that lecithin liposomes enhance wound healing through antioxidant activity. These findings further support the potential beneficial effects of PRF-110 on the wound healing process.
Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, expressed his encouragement with the favorable wound healing data from the human clinical trials. He believes that PRF-110 has the potential not only to provide effective pain relief but also to promote normal wound healing and prevent scar formation, which could significantly enhance post-surgical recovery and patient outcomes.
PainReform is on track to report top-line results from the Phase 3 trial of PRF-110 in the second half of 2024. These results are expected to further inform the regulatory submission process and potential commercialization plans.
PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the company’s lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. It is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed to provide localized and extended postoperative analgesia. The company’s proprietary extended-release drug-delivery system aims to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
For more information about PainReform and PRF-110, please visit www.painreform.com.